Highest-materiality recent filing
Advanced Biomed completes AI pivot with acquisition of Acellent Technologies
Acquired 100% of Acellent Technologies (HK) for 270,000 shares at $4/share, valued at $1.08M; closed April 30, 2026.
Advanced Biomed regains Nasdaq compliance after reverse stock split; stock remains listed
Received Panel decision on March 12, 2026 confirming compliance with Minimum Bid Price Rule.
Advanced Biomed announces 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse split effective Feb 20, 2026; every 20 shares become 1 share, par value unchanged $0.001.
Advanced Biomed enters supplemental agreement for $6.9M debt repayment from spun-off subsidiary
Advanced Biomed acknowledged $6,925,549 debt owed by Advanced Biomed (HK) Limited, its spun-off subsidiary.
Failed to regain minimum $1.00 bid price by Jan 14, 2026; Nasdaq notified delisting effective Jan 27, 2026.
Advanced Biomed sells Hong Kong subsidiary for $23K; moves clinical trials to Taiwan
Sold 100% of Advanced Biomed (HK) Limited and all IP of Shanghai Sglcell Biotech Co., Ltd. for US$23,000.
Advanced Biomed receives Nasdaq bid price deficiency notice; has 180 days to regain compliance
Nasdaq notified ADVB on July 18, 2025, of bid price below $1.00 for 32 consecutive business days.
Advanced Biomed secures up to $25M equity purchase agreement with Helena Global
Company enters purchase agreement with HELENA GLOBAL for up to $25M of common stock.
On May 23, 2025, the Board of Directors of Advanced Biomed Inc. (the “Company”) accepted the resignation of Dr. Hung To Pau from the Board of Directors for personal reasons.
On May 23, 2025, the Board of Directors of the Company appointed Mr. Steven I-Fang Cheng as a member of the Board of Director, effective May 23, 2025.
Max materiality 0.90 · Median 0.60 · Most common event other_material